Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Cambridge Scientists Find Cause of Immune Failure

November 3, 2010 7:29 am | News | Comments

Researchers at the University of Cambridge hope to revolutionise cancer therapy after discovering one of the reasons why many previous attempts to harness the immune system to treat cancerous tumours have failed.


FDA Wants More Time to Review Ipilimumab

November 3, 2010 7:15 am | News | Comments

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has determined that additional time is required to complete the review of the biologics license application for ipilimumab in pre-treated advanced melanoma.


Algeta Presents Alpharadin Data

November 3, 2010 7:08 am | News | Comments

Algeta ASA presented an analysis based on clinical experience with Alpharadin from its phase 1 and phase 2 programs. The analysis concluded that Alpharadin is safe and easy to use, requires no specialized equipment, and is convenient for patients.


Medtronic Receives Stent Go-Ahead

November 3, 2010 6:33 am | News | Comments

Medtronic, the world's largest medical device maker, said it received U.S. regulatory approval for an implant to prevent a type of aneurysm caused by ruptures of the aortic artery.


Possible New Approach to Parkinson's Disease

November 3, 2010 6:31 am | by Lauran Neergaard | News | Comments

Parkinson's disease may stem from an energy crisis in the brain. If true, it points to a new approach for Parkinson's: Giving a boost to a key power switch inside brain cells in hopes of slowing the disease's inevitable march instead of just treating symptoms.


Clinical Trial Advisor Arrest for Insider Trading

November 3, 2010 6:28 am | by Larry Neumeister | News | Comments

A French doctor hired as an adviser on a clinical trial for a liver disease drug passed along secrets about the results, including information about a death, to a hedge fund portfolio manager who dodged $30 million in losses as a result.


CVS Profits Drop 20% for Quarter

November 3, 2010 6:24 am | by Matthew Perrone | News | Comments

CVS Caremark Corp. reported a drop in third-quarter profit as its pharmacy benefit unit continued losing business from previously canceled contracts.


Biogen Cutting 13% of Work Force

November 3, 2010 6:23 am | News | Comments

Biotechnology company Biogen Idec Inc. said it is laying off 13 percent of its work force, or 650 employees, in a restructuring and cost-cutting move. Weston, Mass. based Biogen will have 4,275 employees after the cuts.


Gilead Therapies Suppress HCV

November 2, 2010 8:54 am | News | Comments

Gilead Sciences, Inc. announced data from a Phase 2a study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus.


Cell Therapeutics Submits MAA to EMA

November 2, 2010 8:48 am | News | Comments

Cell Therapeutics, Inc. announced that it has submitted a marketing authorization application to the European Medicines Agency for Pixuvri for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.


FDA Grants CF Drug Orphan Drug Status

November 2, 2010 8:37 am | News | Comments

Discovery Laboratories, Inc. announced that the Food and Drug Administration has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis.


NuPathe Submits Zelrix NDA

November 2, 2010 8:34 am | News | Comments

NuPathe Inc. announced that the company submitted a New Drug Application for Zelrix to the U.S. Food and Drug Administration. Zelrix is the first ever submission to the FDA of a transdermal patch for the treatment of migraine.


XOMA Discussing Botulinum Toxin Treatment

November 2, 2010 8:29 am | News | Comments

XOMA Ltd announced several presentations that will highlight advances in the company's biodefense program and particularly in the development of XOMA 3AB, an antibody co-mixture that binds to distinct regions of botulinum toxin type A.


Hyperion UCD Drug Succeeds in Phase 3 Study

November 2, 2010 8:21 am | News | Comments

Hyperion Therapeutics, Inc. announced that the company’s phase 3 pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for the treatment of urea cycle disorders, met its primary endpoint.


Antisense Publishes Phase 2b Trial Results

November 2, 2010 8:17 am | News | Comments

The investigated drug trabedersen (AP 12009) is a gene silencing antisense compound – a phosphorothioate oligodeoxynucleotide – designed to selectively downregulate the production of transforming growth factor-beta 2 (TGF-?2) at the translational level.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.